Avenir Corporation’s Pacira BioSciences PCRX Stock Holding History

Avenir Corporation’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-20,080	Closed	-$987K	–	67
2018 Q3	$987K	Hold	20,080	–	–	0.11%	50
2018 Q2	$644K	Sell	20,080 -2,570	-11%	-$88.7K	0.07%	53
2018 Q1	$706K	Buy	22,650 +6,780	+43%	+$241K	0.08%	53
2017 Q4	$724K	Buy	15,870 +3,750	+31%	+$149K	0.07%	55
2017 Q3	$455K	Buy	12,120 +2,100	+21%	+$84.5K	0.04%	58
2017 Q2	$478K	Buy	10,020 +2,120	+27%	+$98.4K	0.04%	58
2017 Q1	$360K	Hold	7,900	–	–	0.03%	61
2016 Q4	$255K	Buy	7,900 +400	+5%	+$13.3K	0.02%	64
2016 Q3	$257K	Buy	+7,500	New	+$294K	0.02%	62
2016 Q1	–	Sell	-2,750	Closed	-$211K	–	69
2015 Q4	$211K	Buy	+2,750	New	+$156K	0.02%	67

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Avenir Corporation's PCRX Position: Q4 2018 in Review

Avenir Corporation sold out of Pacira BioSciences (PCRX) in Q4 2018, closing a stake of 20,080 shares — an estimated $987K sold.

Avenir Corporation first reported a position in PCRX in Q4 2015 and held it in 10 quarters. The position peaked at $987K in Q3 2018. 208 funds tracked by Wall St. Rank hold PCRX as of Q4 2018.

Avenir Corporation reported no remaining Pacira BioSciences position as of Q4 2018 after selling out during the quarter.
Avenir Corporation sold 20,080 Pacira BioSciences shares in Q4 2018, an estimated $987K.
Avenir Corporation first reported a position in Pacira BioSciences in Q4 2015 and held it in 10 quarters.
Avenir Corporation's Pacira BioSciences position peaked at $987K in Q3 2018.
208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2018.

Based on Avenir Corporation's 13F filing for Q4 2018, filed 13 Feb 2019.